clofibrate has been researched along with l 663536 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Burczynski, FJ; Gong, Y; Wang, G; Yan, J | 1 |
Adair, J; Aliczki, M; Barnes, C; Goldberg, SR; Haller, J; Heishman, SJ; Justinova, Z; Lecca, S; Luchicchi, A; Mascia, P; Panlilio, LV; Pistis, M; Redhi, GH; Yasar, S | 1 |
2 other study(ies) available for clofibrate and l 663536
Article | Year |
---|---|
Regulation of liver fatty acid binding protein expression by clofibrate in hepatoma cells.
Topics: Anilides; Animals; Carcinoma, Hepatocellular; Catalase; Cell Line, Tumor; Clofibrate; Fatty Acid-Binding Proteins; Fluoresceins; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Hepatocytes; Humans; Hydrogen Peroxide; Indoles; Liver Neoplasms; Oxidative Stress; PPAR alpha; Rats; RNA Stability; RNA, Messenger; Superoxide Dismutase | 2010 |
Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.
Topics: Action Potentials; Animals; Clofibrate; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Hypolipidemic Agents; Indoles; Male; Neurons; Nicotine; Nucleus Accumbens; PPAR alpha; Rats; Rats, Sprague-Dawley; Reward; Saimiri; Secondary Prevention; Self Administration; Tobacco Use Disorder; Ventral Tegmental Area | 2012 |